Prime Medicine director granted 75,000 stock options

Prime Medicine director Kelly Michael Aaron received a new stock option grant that could convert into common shares in the future.

Rhea-AI Filing Summary

Prime Medicine director Kelly Michael Aaron received a new stock option grant that could convert into common shares in the future. The award covers 75,000 shares of common stock at an exercise price of $3.06 per share and expires on June 5, 2036. According to the terms, the option vests in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual stockholder meeting, as long as Aaron continues serving the company through that vesting date. After this grant, Aaron holds stock options for 75,000 underlying shares directly.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Kelly Michael Aaron

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	75,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 75,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Key Figures

Option grant size: 75,000 shares Exercise price: $3.06 per share Expiration date: June 5, 2036 +2 more

5 metrics

Option grant size 75,000 shares Underlying common stock in new option award

Exercise price $3.06 per share Strike price for the stock option

Expiration date June 5, 2036 Option term end date

Vesting latest date June 5, 2027 Latest possible full vesting date, subject to service

Shares after transaction 75,000 options Total options held following this grant

Key Terms

Stock Option (right to buy), exercise price, expiration date, vest in full, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 3.0600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-05T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in full financial

"The shares subject to this option shall vest in full upon the earlier of"

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Prime Medicine (PRME) director Kelly Michael Aaron report in this Form 4?

Kelly Michael Aaron reported receiving a stock option grant for 75,000 underlying shares of Prime Medicine common stock. The option was granted at a $3.06 exercise price and represents compensation, not an open-market stock purchase or sale.

How many Prime Medicine (PRME) shares are covered by Aaron’s new stock option?

The new stock option granted to Kelly Michael Aaron covers 75,000 underlying shares of Prime Medicine common stock. These shares can be acquired in the future if the option vests and is exercised at the stated $3.06 per-share price.

What is the exercise price and expiration date of Aaron’s PRME stock option?

The option has an exercise price of $3.06 per share and an expiration date of June 5, 2036. Aaron may choose to exercise it after vesting, subject to remaining within this option term and paying the exercise price.

When do Kelly Michael Aaron’s Prime Medicine options vest?

The options vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual meeting of stockholders. Vesting requires Aaron to maintain continuous service with the company through the applicable vesting date.

Did Kelly Michael Aaron buy or sell Prime Medicine (PRME) shares on the market?

The filing shows a grant of stock options, not a market trade in Prime Medicine shares. The transaction is coded as an acquisition award, reflecting compensation, and does not involve buying or selling common stock on a public market.

How many Prime Medicine options does Aaron hold after this transaction?

Following this grant, Kelly Michael Aaron holds stock options representing 75,000 underlying shares of Prime Medicine common stock directly. This entire position comes from the newly awarded option reported in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Michael Aaron

(Last) (First) (Middle)

C/O PRIME MEDICINE, INC.

60 FIRST STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Prime Medicine, Inc. [ PRME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.06	06/05/2026		A		75,000		(1)	06/05/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Remarks:

	/s/ Ryan Brown, attorney-in-fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)